secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001193125-23-171145
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics shareholders elect two Class III directors, ratify auditor, approve charter amendment
--------------------------------------------------------------------------------

- Krishna Vaddi, Ph.D. and Mardi C. Dier elected as Class III directors with ~27M votes for each.
- Ernst & Young LLP ratified as independent auditor for FY2023 with 28.78M for, 6,022 against.
- Amendment to certificate of incorporation for officer exculpation passed with 22.71M for, 97,553 against.
- All proposals passed; broker non-votes reported for director elections and charter amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/0001193125-23-171145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/d453914d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-171145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer